ARCT Arcturus Therapeutics Holdings Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1768224 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-68.7%
TTM net income YoY-30.8%
TTM EPS YoY-26.0%
Revenue 3-yr CAGR-53.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-311.2%
Net margin-285.9%
FCF margin-204.7%
EBITDA margin-302.9%
Returns
ROE-44.4%
ROA-35.1%
ROIC (approx.)-533.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets21.6%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue-0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.30M | $2.96M | $2.06M | $7.20M | $17.15M | $28.30M | $29.38M | $22.77M |
| R&D expense | $17.00M | $17.52M | $21.53M | $24.48M | $23.27M | $29.58M | $34.89M | $43.78M |
| SG&A expense | $10.48M | $10.99M | $9.46M | $14.03M | $10.40M | $10.34M | $11.31M | $12.38M |
| Operating income | -$9.19M | -$25.55M | -$28.93M | -$31.31M | -$16.51M | -$11.62M | -$16.83M | -$33.39M |
| Pretax income | -$7.41M | -$23.79M | — | -$29.08M | -$13.45M | -$9.18M | -$14.08M | -$30.01M |
| Income tax | $0 | $0 | — | — | $0 | $4,000 | $0 | -$4,000 |
| Net income | -$7.41M | -$23.79M | -$26.96M | -$29.08M | -$13.45M | -$9.18M | -$14.08M | -$30.00M |
| EBITDA | -$8.59M | -$24.95M | -$28.27M | -$30.62M | -$15.71M | -$10.82M | -$16.02M | -$32.58M |
| EPS (basic) | -0.26 | -0.84 | -0.95 | — | -0.49 | -0.34 | -0.52 | — |
| EPS (diluted) | -0.26 | -0.84 | -0.95 | — | -0.49 | -0.34 | -0.52 | — |
| Weighted avg. shares (diluted) | 28.44M | 28.42M | 28.42M | — | 27.19M | 27.13M | 27.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $184.82M | $191.48M | $211.38M | $230.91M | $180.36M | $196.47M | $216.95M | $293.91M |
| Receivables | $1.25M | $1.81M | $1.34M | $5.56M | $7.95M | $17.20M | $14.57M | $3.97M |
| Current assets | $189.40M | $197.16M | $216.88M | $241.45M | $249.20M | $274.50M | $278.79M | $305.98M |
| PP&E, net | $4.81M | $5.36M | $6.08M | $6.74M | $7.42M | $8.09M | $8.87M | $9.53M |
| Total assets | $215.32M | $224.31M | $245.41M | $271.15M | $282.34M | $309.27M | $331.79M | $344.07M |
| Current liabilities | $28.34M | $33.54M | $34.37M | $36.38M | $31.70M | $46.52M | $49.41M | $65.49M |
| Long-term debt | — | — | — | — | — | — | $15.00M | — |
| Total debt | — | — | — | — | — | — | $15.00M | — |
| Total liabilities | $46.59M | $52.50M | $54.05M | $57.16M | $57.78M | $78.22M | $98.03M | $103.09M |
| Shareholders' equity | $168.73M | $171.81M | $191.36M | $213.99M | $224.56M | $231.05M | $233.76M | $240.98M |
| Net debt | — | — | — | — | — | — | -$201.95M | — |
| Shares outstanding | 28.46M | 28.42M | 28.42M | 28.41M | 27.23M | 27.15M | — | 27.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.91M | -$19.91M | -$19.44M | -$16.23M | -$17.15M | -$5.75M | -$35.14M | -$284,000 |
| Capital expenditure | $52,000 | $0 | $0 | -$88,000 | $181,000 | $0 | $137,000 | $0 |
| Free cash flow | -$6.96M | -$19.91M | -$19.44M | -$16.14M | -$17.33M | -$5.75M | -$35.27M | -$284,000 |
| Investing cash flow | -$52,000 | $18,000 | $34,000 | $88,000 | -$181,000 | $0 | -$137,000 | $0 |
| Financing cash flow | $291,000 | $0 | $16,000 | $11.69M | $1.23M | -$14.73M | $15.20M | $134,000 |
| Depreciation & amortization | $600,000 | $600,000 | $658,000 | $682,000 | $800,000 | $800,000 | $801,000 | $819,000 |
| Stock-based compensation | $4.04M | $4.23M | $4.33M | $6.82M | $5.73M | $6.20M | $6.66M | $8.98M |
Free plan shows the latest 8 periods; Pro shows all 34 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.